×
About 27,648 results

ALLMedicine™ Multiple Myeloma Center

Research & Reviews  9,136 results

Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in mye...
https://doi.org/10.1038/s41556-021-00766-y 10.1016/j.cell.2010.02.027 10.1038/nature24297 10.1038/nature22794 10.1038/s41467-018-05729-w 10.1038/ncomms7683 10.1038/s41556-020-0547-3 10.1016/j.ccell.2020.06.006 10.1038/leu.2016.211 10.1371/journal.pone.0206368 10.1038/nprot.2014.006 10.1038/nmeth.3734 10.1016/j.cels.2016.10.021 10.1038/s41591-018-0269-2 10.1182/blood-2009-12-261032 10.1038/s41588-020-00726-6 10.1016/j.exphem.2018.09.004 10.1038/s41586-018-0414-6 10.1126/science.aax0249 10.1038/ncomms15599 10.1038/s42003-019-0554-8 10.1016/j.celrep.2018.06.035 10.1038/nmeth.4463 10.1074/jbc.275.4.2986 10.1371/journal.pgen.1006600 10.1093/bioinformatics/btw187 10.1016/j.celrep.2019.05.004 10.1016/j.celrep.2018.12.016 10.1182/blood-2017-09-808063 10.1038/nbt.1630 10.1038/s41588-019-0538-0 10.1038/nmeth.4401 10.1073/pnas.0912260107 10.1016/j.bbrc.2013.08.087 10.3389/fimmu.2018.02551 10.1016/j.celrep.2015.06.059 10.1158/1078-0432.CCR-19-0647 10.1182/blood-2008-08-174946 10.1038/s41590-019-0468-0 10.3389/fimmu.2019.01121 10.1101/gr.265520.120 10.1126/science.aal2380 10.1038/nmeth.4396 10.1093/bioinformatics/btu170 10.1093/bioinformatics/bts635 10.1186/1471-2105-12-323 10.1093/bioinformatics/btu638 10.1038/s41590-018-0276-y 10.1126/science.1254257 10.1126/science.aad0501 10.1093/bioinformatics/bty316 10.1038/nmeth.3364 10.1186/1471-2105-11-367 10.1093/bioinformatics/btp616 10.1093/nar/gks042 10.1016/j.cell.2017.10.044 10.1073/pnas.0506580102 10.1093/bioinformatics/btr260 10.1016/j.cels.2015.12.004 10.1186/s13059-017-1382-0 10.1186/s13059-017-1349-1 10.1038/nbt.4096 10.1038/s41467-017-02391-6 10.1182/blood.2019004547 10.1101/gr.1239303 10.1186/s13059-021-02461-5 10.1038/nmeth.1528 10.1038/nature07509 10.1038/s41588-021-00790-6 10.1038/s41587-020-0439-x 10.1038/s41408-021-00421-7 10.1038/s41467-019-09982-5 10.1016/j.molcel.2018.06.044
Nature Cell Biology; Frede J, Anand P et. al.

Oct 23rd, 2021 - While there is extensive evidence for genetic variation as a basis for treatment resistance, other sources of variation result from cellular plasticity. Using multiple myeloma as an example of an incurable lymphoid malignancy, we show how cancer c...

Tissue Collection for Studies of Lymph Cancer
https://clinicaltrials.gov/ct2/show/NCT01676805

Oct 22nd, 2021 - Background: An estimated 79,190 people living in the United States will be diagnosed with lymphoma in 2012, including 9,060 cases of HL, 70,130 cases of non-Hodgkin s lymphoma (NHL) and multiple cases of adult T-cell leukemia/lymphoma. Laboratory ...

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT04933539

Oct 22nd, 2021 - Background: Smoldering multiple myeloma (SMM) is a precursor condition to MM defined by the clinical parameters of M-protein >=3.0 g/dL or bone marrow plasma cells >=10%, and absence of end organ disease. Patients with high-risk SMM have a risk of...

Evaluation of Cardiac Adverse Events Associated with Carfilzomib Using a Japanese Real-...
https://doi.org/10.1159/000519687
Oncology Nakao S, Uchida M et. al.

Oct 22nd, 2021 - Carfilzomib is a proteasome inhibitor widely used for the treatment of multiple myeloma. However, cardiac adverse events (CAEs) are a serious side effect of carfilzomib administration. Observational studies based on systematic reviews and real-wor...

Comprehensive geriatric assessment in newly diagnosed older myeloma patients: a multice...
https://doi.org/10.1093/ageing/afab211
Age and Ageing; Yao Y, Sui WW et. al.

Oct 22nd, 2021 - Multiple myeloma is a disease of the older people, whose prognoses are highly heterogeneous. The International Myeloma Working Group (IMWG) proposed a geriatric assessment (GA) based on age, functional status and comorbidities to discriminate betw...

see more →

Guidelines  32 results

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and fo...
https://doi.org/10.1016/j.annonc.2020.11.014
Annals of Oncology : Official Journal of the European Soc... Dimopoulos MA, Moreau P et. al.

Feb 8th, 2021 - Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.|2021|Dimopoulos MA,Moreau P,Terpos E,Mateos MV,Zweegman S,|diagnosis,epidemiology,therapy,

KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological mali...
https://doi.org/10.1016/j.kint.2020.07.012
Kidney International; Małyszko J, Bamias A et. al.

Dec 6th, 2020 - The bidirectional relationship between cancer and chronic kidney disease (CKD) is complex. Patients with cancer, particularly those with hematological malignancies such as multiple myeloma and lymphoma, are at increased risk of developing acute ki...

Mobilization and Exercise Intervention for Patients With Multiple Myeloma: Clinical Pra...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781094
Physical Therapy; Jeevanantham D, Rajendran V et. al.

Sep 26th, 2020 - Individuals with multiple myeloma (MM) often have reduced functional performance due to the cancer itself or as a direct side effect of cancer treatments. Physical therapy is a part of cancer rehabilitation; however, no guidelines are available to...

Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline.
https://doi.org/10.1200/JCO.18.02096
Journal of Clinical Oncology : Official Journal of the Am... Mikhael J, Ismaila N et. al.

Apr 2nd, 2019 - To provide evidence-based recommendations on the treatment of multiple myeloma to practicing physicians and others. ASCO and Cancer Care Ontario convened an Expert Panel of medical oncology, surgery, radiation oncology, and advocacy experts to con...

Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patien...
https://doi.org/10.1111/joim.12882
Journal of Internal Medicine; Bringhen S, Milan A et. al.

Feb 7th, 2019 - The novel proteasome inhibitor carfilzomib alone or in combination with other agents is already one of the standard therapies for relapsed and/or refractory multiple myeloma (MM) patients and produces impressive response rates in newly diagnosed M...

see more →

Drugs  139 results see all →

Clinicaltrials.gov  418 results

Tissue Collection for Studies of Lymph Cancer
https://clinicaltrials.gov/ct2/show/NCT01676805

Oct 22nd, 2021 - Background: An estimated 79,190 people living in the United States will be diagnosed with lymphoma in 2012, including 9,060 cases of HL, 70,130 cases of non-Hodgkin s lymphoma (NHL) and multiple cases of adult T-cell leukemia/lymphoma. Laboratory ...

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT04933539

Oct 22nd, 2021 - Background: Smoldering multiple myeloma (SMM) is a precursor condition to MM defined by the clinical parameters of M-protein >=3.0 g/dL or bone marrow plasma cells >=10%, and absence of end organ disease. Patients with high-risk SMM have a risk of...

Mobilization of Stem Cells With AMD3100 (Plerixafor) in Combination With G-CSF in Multiple Myeloma Patients
https://clinicaltrials.gov/ct2/show/NCT05087212

Oct 21st, 2021 - The study duration consists of: An up-to 30-day screening, an up-to 8-day intervention and CD34+ cells apheresis and a follow up for 30 days (+7 days) post last dose of plerixafor, or the initiation of ablative chemotherapy, or the first dose of G...

Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT01572480

Oct 21st, 2021 - Background: SMM is a precursor condition to MM defined by the clinical parameters of M-protein >= 3.0 g/dL or bone marrow plasma cells >= 10% and absence of end organ disease. Risk of progression of high risk SMM at 5 years is 72-75% with median t...

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (...
https://clinicaltrials.gov/ct2/show/NCT05083169

Oct 19th, 2021 - Teclistamab is a novel B-cell maturation antigen (BCMA) bispecific antibody that is being evaluated to treat participants with multiple myeloma, an incurable malignant plasma cell disorder. The primary hypothesis of this study is that Tec-Dara wil...

see more →

News  1,321 results

BTK Inhibitors, PI3K Inhibitors, and CAR T-Cell Therapy Shake Up Hematologic Malignancies Armamentarium
https://www.onclive.com/view/btk-inhibitors-pi3k-inhibitors-and-car-t-cell-therapy-shake-up-hematologic-malignancies-armamentarium

Oct 13th, 2021 - BTK inhibitors, PI3K inhibitors, and CAR T-cell therapies have changed the treatment landscape of many hematologic malignancies, said Harry Paul Erba, MD, PhD, who added that the evolving paradigms underscore the need for individualized decision m...

Dr. Patel on the Potential Utility of Elranatamab in Multiple Myeloma
https://www.onclive.com/view/dr-patel-on-the-potential-utility-of-elranatamab-in-multiple-myeloma

Oct 6th, 2021 - Krina K. Patel, MD, MSc, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the potential utility of elranatamab (PF-06863135) in multiple myeloma. Elra...

JTCC and Georgetown’s Alliance in Cancer Research Achieves New Level With Immunotherapy Breakthrough
https://www.onclive.com/view/jtcc-and-georgetown-s-alliance-in-cancer-research-achieves-new-level-with-immunotherapy-breakthrough

Oct 6th, 2021 - It was 5:00 PM on a Monday, and Andrew Pecora, MD, FACP, CPE, was just wrapping up his practice for the day when one of his nurses came to the door, asking if he could see one more patient. ‘This is a 19-year-old that they just rolled in, and he’...

Stemness Inhibitor Tested in Rare Hematologic Cancer
https://www.onclive.com/view/stemness-inhibitor-tested-in-rare-hematologic-cancer

Oct 6th, 2021 - Andrew A. Lane, MD, PhD SL-401, a novel therapy that targets a cancer stemness pathway, is being investigated in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in a phase I/II trial that may pave the way for its approval for t...

Dr. Furman on the Safety of Acalabrutinib in Hematologic Malignancies
https://www.onclive.com/view/dr-furman-on-the-safety-of-acalabrutinib-in-hematologic-malignancies

Oct 6th, 2021 - Richard R. Furman, MD, a member of the Lymphoma/Myeloma Service in the Division of Hematology/Oncology and director of the CLL Research Center at Weill Cornell Medical College, and attending physician at New York-Presbyterian Hospital, discusses t...

see more →

Patient Education  13 results see all →